In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum. / Faber, Jens; Ballegaard, Søren; Ørsted, Nanna; Eldrup, Ebbe; Karpatschof, Benny; Gyntelberg, Finn; Hecquet, Sofie Korsgaard; Gjedde, Albert.

In: Frontiers in Neuroscience, Vol. 17, 1067098, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Faber, J, Ballegaard, S, Ørsted, N, Eldrup, E, Karpatschof, B, Gyntelberg, F, Hecquet, SK & Gjedde, A 2023, 'In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum', Frontiers in Neuroscience, vol. 17, 1067098. https://doi.org/10.3389/fnins.2023.1067098

APA

Faber, J., Ballegaard, S., Ørsted, N., Eldrup, E., Karpatschof, B., Gyntelberg, F., Hecquet, S. K., & Gjedde, A. (2023). In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum. Frontiers in Neuroscience, 17, [1067098]. https://doi.org/10.3389/fnins.2023.1067098

Vancouver

Faber J, Ballegaard S, Ørsted N, Eldrup E, Karpatschof B, Gyntelberg F et al. In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum. Frontiers in Neuroscience. 2023;17. 1067098. https://doi.org/10.3389/fnins.2023.1067098

Author

Faber, Jens ; Ballegaard, Søren ; Ørsted, Nanna ; Eldrup, Ebbe ; Karpatschof, Benny ; Gyntelberg, Finn ; Hecquet, Sofie Korsgaard ; Gjedde, Albert. / In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum. In: Frontiers in Neuroscience. 2023 ; Vol. 17.

Bibtex

@article{c197e65e3e8148e78f6870a08a4cca74,
title = "In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum",
abstract = "BACKGROUND: The autonomic nervous system (ANS) maintains glucose homeostasis. While higher than normal glucose levels stimulate the ANS toward reduction, previous findings suggest an association between sensitivity to, or pain from, pressure at the chest bone (pressure or pain sensitivity, PPS) and activity of the ANS. A recent randomized controlled trial (RCT) of type 2 diabetes (T2DM) suggested that addition of an experimental, non-pharmacological intervention more effectively than conventional treatment lowered the levels of both PPS and HbA1c.MATERIALS AND ANALYSES: We tested the null hypothesis that conventional treatment (n = 60) would reveal no association between baseline HbA1c and normalization of HbA1c in 6 months, related to change of PPS. We compared the changes of HbA1c in PPS reverters who experienced a minimum reduction of 15 units of PPS and in PPS non-reverters who experienced no reduction. Depending on the result, we tested the association in a second group of participants with addition of the experimental program (n = 52).RESULTS: In the conventional group, PPS reverters experienced normalization of HbA1c that corrected the basal increase, thus disproving the null hypothesis. With the addition of the experimental program, PPS reverters experienced similar reduction. The reduction of HbA1c among reverters averaged 0.62 mmol/mol per mmol/mol increase of baseline HbA1c (P < 0.0001 compared to non-reverters). For baseline HbA1c ≥ 64 mmol/mol, reverters averaged 22% reduction of HbA1c (P < 0.01).CONCLUSION: In consecutive analyses of two different populations of individuals with T2DM, we demonstrated that the higher the baseline HbA1c, the greater the reduction of HbA1c but only in individuals with a concomitant reduction of sensitivity to PPS, suggesting a homeostatic effect of the autonomic nervous system on glucose metabolism. As such, ANS function, measured as PPS, is an objective measure of HbA1c homeostasis. This observation may be of great clinical importance.",
author = "Jens Faber and S{\o}ren Ballegaard and Nanna {\O}rsted and Ebbe Eldrup and Benny Karpatschof and Finn Gyntelberg and Hecquet, {Sofie Korsgaard} and Albert Gjedde",
note = "Copyright {\textcopyright} 2023 Faber, Ballegaard, {\O}rsted, Eldrup, Karpatschof, Gyntelberg, Hecquet and Gjedde.",
year = "2023",
doi = "10.3389/fnins.2023.1067098",
language = "English",
volume = "17",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - In Type 2 Diabetes Mellitus, normalization of hemoglobin A1c accompanies reduced sensitivity to pressure at the sternum

AU - Faber, Jens

AU - Ballegaard, Søren

AU - Ørsted, Nanna

AU - Eldrup, Ebbe

AU - Karpatschof, Benny

AU - Gyntelberg, Finn

AU - Hecquet, Sofie Korsgaard

AU - Gjedde, Albert

N1 - Copyright © 2023 Faber, Ballegaard, Ørsted, Eldrup, Karpatschof, Gyntelberg, Hecquet and Gjedde.

PY - 2023

Y1 - 2023

N2 - BACKGROUND: The autonomic nervous system (ANS) maintains glucose homeostasis. While higher than normal glucose levels stimulate the ANS toward reduction, previous findings suggest an association between sensitivity to, or pain from, pressure at the chest bone (pressure or pain sensitivity, PPS) and activity of the ANS. A recent randomized controlled trial (RCT) of type 2 diabetes (T2DM) suggested that addition of an experimental, non-pharmacological intervention more effectively than conventional treatment lowered the levels of both PPS and HbA1c.MATERIALS AND ANALYSES: We tested the null hypothesis that conventional treatment (n = 60) would reveal no association between baseline HbA1c and normalization of HbA1c in 6 months, related to change of PPS. We compared the changes of HbA1c in PPS reverters who experienced a minimum reduction of 15 units of PPS and in PPS non-reverters who experienced no reduction. Depending on the result, we tested the association in a second group of participants with addition of the experimental program (n = 52).RESULTS: In the conventional group, PPS reverters experienced normalization of HbA1c that corrected the basal increase, thus disproving the null hypothesis. With the addition of the experimental program, PPS reverters experienced similar reduction. The reduction of HbA1c among reverters averaged 0.62 mmol/mol per mmol/mol increase of baseline HbA1c (P < 0.0001 compared to non-reverters). For baseline HbA1c ≥ 64 mmol/mol, reverters averaged 22% reduction of HbA1c (P < 0.01).CONCLUSION: In consecutive analyses of two different populations of individuals with T2DM, we demonstrated that the higher the baseline HbA1c, the greater the reduction of HbA1c but only in individuals with a concomitant reduction of sensitivity to PPS, suggesting a homeostatic effect of the autonomic nervous system on glucose metabolism. As such, ANS function, measured as PPS, is an objective measure of HbA1c homeostasis. This observation may be of great clinical importance.

AB - BACKGROUND: The autonomic nervous system (ANS) maintains glucose homeostasis. While higher than normal glucose levels stimulate the ANS toward reduction, previous findings suggest an association between sensitivity to, or pain from, pressure at the chest bone (pressure or pain sensitivity, PPS) and activity of the ANS. A recent randomized controlled trial (RCT) of type 2 diabetes (T2DM) suggested that addition of an experimental, non-pharmacological intervention more effectively than conventional treatment lowered the levels of both PPS and HbA1c.MATERIALS AND ANALYSES: We tested the null hypothesis that conventional treatment (n = 60) would reveal no association between baseline HbA1c and normalization of HbA1c in 6 months, related to change of PPS. We compared the changes of HbA1c in PPS reverters who experienced a minimum reduction of 15 units of PPS and in PPS non-reverters who experienced no reduction. Depending on the result, we tested the association in a second group of participants with addition of the experimental program (n = 52).RESULTS: In the conventional group, PPS reverters experienced normalization of HbA1c that corrected the basal increase, thus disproving the null hypothesis. With the addition of the experimental program, PPS reverters experienced similar reduction. The reduction of HbA1c among reverters averaged 0.62 mmol/mol per mmol/mol increase of baseline HbA1c (P < 0.0001 compared to non-reverters). For baseline HbA1c ≥ 64 mmol/mol, reverters averaged 22% reduction of HbA1c (P < 0.01).CONCLUSION: In consecutive analyses of two different populations of individuals with T2DM, we demonstrated that the higher the baseline HbA1c, the greater the reduction of HbA1c but only in individuals with a concomitant reduction of sensitivity to PPS, suggesting a homeostatic effect of the autonomic nervous system on glucose metabolism. As such, ANS function, measured as PPS, is an objective measure of HbA1c homeostasis. This observation may be of great clinical importance.

U2 - 10.3389/fnins.2023.1067098

DO - 10.3389/fnins.2023.1067098

M3 - Journal article

C2 - 37389368

VL - 17

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

M1 - 1067098

ER -

ID: 359240882